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Introduction 
 
Reason for action 
Need for ALZ to raise its profile over the next 3 – 5 years to 
maximise access to donor contributions and fulfil its 
primary purpose as a best in class centre of expertise for 
the research, prevention, treatment and care in 
dementia related conditions.            
 
In order to do this, a number of options have been 
evaluated (see supporting analysis) to provide ALZ with 
the most effective strategy to meet the above objective. 
 
International expansion is the core element of our 
proposal to ALZ and our details findings, methodology 
and recommendations are presented below.  To monitor 
the success of the proposed strategy a range of 
measures are suggested. 
 
Vision 
A radically improved world for all people with dementia 
 
Entering an overseas market 
As shown in table ii [Harrel and Keifer model – measure of 
attractiveness vs compatibility/capability] the following 
countries offer the best strategic fit: 
 
Our country selections: 
- Primary 
Norway 
Sweden 
Germany 
Potential to approach Nordics as one group: to include 
Norway, Sweden, Denmark with Germany as separate due 
to size 
 
Drivers for choice of countries: 
All country data demonstrate that, in line with the UK, a 
trend towards an increasingly ageing population, along 
with state intervention and increasing public expenditure, 
hence their selection as phase 1 entry markets.  All 
geographies also have a relative cultural closeness and 
proximity to the core UK market.   
 
- Secondary 
Netherlands 
USA 
Canada 
Commentary 
USA could offer a partner link in terms of research 
developments and expertise, with a closer tie possible 
with ADI.  
 
With all European markets, there is the opportunity to 
gain information on care and treatment regimes, and for 
ALZ to offer an aligned European view on dementia care.  
Although Italy also has one of the highest ratio of 
population over 65+ to 15, data is currently incomplete 
and spend relatively low. 
 
 
Market entry strategy 
[Reference to 12C model] 
 
Primary markets 
UK: Merge with Friends of ADI in the UK and acquire 
relevant charities, especially where they have an existing 
centre of marketing expertise, for instance Mind. 
Europe: Recommend merger and acquisition of material 
charities in Europe based on donors, funding strength and 
profile and brand alignment.  For both entry strategies, 
the aim would be to brand all entities as ALZ, hence the 
option to go for merger and acquisition rather than the 
looser power relationship with a JV. 
 
Secondary markets 
USA: leverage power of ADI link and draw on centre of 
research expertise through partnerships and 
collaboration. 
 
Success measures 
1. Within the next 5 years, moving from a tier 2 to tier 1 
charity with the UK and Europe, measured in the 
following areas: 
2. Increased brand awareness across chosen market 
spaces and increase in brand equity through 
association with expertise 
3. Stronger research collaborations delivering direct 
benefits to strategic aims as outlined in the 
introduction above 
4. Increased donor and public funding by 30% by 2015 
5. Increased net worth  by 20% by 2015 
6. Being known as the no1 expert in Alzheimer 
treatment, research and care across the UK and 
Europe 
 
Future expansion plans 
Research potential within following markets: 
- Eastern Europe 
- Italy [need data] 
- Japan 
 
Budget/timescales 
Key milestones are 2012 [UK increase in donor funds 
opportunity and ALZ share of this] 
Strategic milestones: 2013 and 2015 so we have idea of 
strategic bridge.  
Budget – cost of acquisition 
Would anticipate increase in budgets particularly campaign 
and research budgets to get ALZ to next level. 
 
Monitoring, control and evaluation 
Refer to Balanced Scorecard and McKinsey 7S 
Key measures: 
- ROI 
- Learning measures: benchmarking, training 
- Number of enquiries by media/channel 
- Market share  
- Acquisition cost per donor 
- Transparency rating? 
- Cash flow management [links to above] 
- Innovation: cutting edge research reports 
- Customer satisfaction: GPs, families, carers 
- Quality control 
- Brand equity and strength 
- Campaign effectiveness 
 
Conclusion and recommendations 
We recommend a phased international market entry 
strategy, within the course of the next 5 years to 2015. 
By introducing core propositions to relevant market spaces 
within this tight timescale, this will increase ALZ’s 
profile, financial strength and influencing power, as well 
as helping to make the UK a leading centre for dementia 
research. 
 
 
